TIDMAMYT
Amryt Pharma PLC
06 January 2021
Amryt to Participate in H.C. Wainwright Virtual BioConnect 2021
Conference
DUBLIN, Ireland, and Boston MA, January 6, 2021, Amryt (Nasdaq:
AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical
company dedicated to developing and commercializing novel
therapeutics to treat patients suffering from serious and
life-threatening rare diseases , is pleased to announce that the
Company will participate in the virtual H.C. Wainwright BioConnect
2021 Conference to be held January 11-14, 2021.
A webcast of Amryt's presentation will be available on demand
from 0600 EST, Monday January 11, 2021 and can be accessed via the
link below:
https://journey.ct.events/view/15a39863-6e27-42a0-b9b8-d659b8c751c6
About Amryt
Amryt is a biopharmaceutical company focused on developing and
delivering innovative new treatments to help improve the lives of
patients with rare and orphan diseases. Amryt comprises a strong
and growing portfolio of commercial and development assets.
Amryt's commercial business comprises two orphan disease
products.
Amryt's lead development candidate, FILSUVEZ (R) (Oleogel-S10)
is a potential treatment for the cutaneous manifestations of
Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin
disorder affecting young children and adults for which there is
currently no approved treatment. FILSUVEZ(R) has been selected as
the brand name for the product. Amryt does not have regulatory
approval for FILSUVEZ(R) to treat EB. In September and October
2020, Amryt reported positive results from its pivotal global Phase
3 trial in EB. The product has been granted Rare Pediatric Disease
Designation and has also received a Fast Track Designation from the
U.S. Food and Drug Administration.
Myalept(R) / Myalepta(R) (metreleptin) is approved in the US
(under the trade name Myalept(R)) as an adjunct to diet as
replacement therapy to treat the complications of leptin deficiency
in patients with congenital or acquired generalized lipodystrophy
(GL) and in the EU (under the trade name Myalepta(R)) for the
treatment of leptin deficiency in patients with congenital or
acquired GL in adults and children two years of age and above and
familial or acquired partial lipodystrophy (PL) in adults and
children 12 years of age and above for whom standard treatments
have failed to achieve adequate metabolic control. Metreleptin is
also approved for lipodystrophy in Japan. Generalised and partial
lipodystrophy are rare disorders characterised by loss or lack of
adipose tissue resulting in the deficiency of the hormone leptin,
produced by fat cells and are associated with severe metabolic
abnormalities including severe insulin resistance, diabetes,
hypertriglyceridemia and fatty liver disease.
Juxtapid(R)/ Lojuxta(R) (lomitapide) is approved as an adjunct
to a low-fat diet and other lipid-lowering medicinal products for
adults with the rare cholesterol disorder, Homozygous Familial
Hypercholesterolaemia ("HoFH") in the US, Canada, Columbia,
Argentina and Japan (under the trade name Juxtapid(R)) and in the
EU and Brazil (under the trade name Lojuxta(R)). HoFH is a rare
genetic disorder which impairs the body's ability to remove low
density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from
the blood, typically leading to abnormally high blood LDL
cholesterol levels in the body from before birth - often ten times
more than people without HoFH - and subsequent aggressive and
premature cardiovascular disease.
In March 2018, Amryt in-licensed a pre-clinical gene-therapy
platform technology, AP103, which offers a potential treatment for
patients with Recessive Dystrophic Epidermolysis Bullosa, a subset
of EB, and is also potentially relevant to other genetic disorders.
For more information on Amryt, including products, please visit
www.amrytpharma.com .
The person making this notification on behalf of Amryt is Rory
Nealon, CFO/COO and Company Secretary.
Forward-Looking Statements
This press release may contain forward-looking statements
containing the words "expect", "anticipate", "intends", "plan",
"estimate", "aim", "forecast", "project" and similar expressions
(or their negative) identify certain of these forward-looking
statements. The forward-looking statements in this announcement are
based on numerous assumptions and Amryt's present and future
business strategies and the environment in which Amryt expects to
operate in the future. Forward-looking statements involve inherent
known and unknown risks, uncertainties and contingencies because
they relate to events and depend on circumstances that may or may
not occur in the future and may cause the actual results,
performance or achievements to be materially different from those
expressed or implied by such forward-looking statements. These
statements are not guarantees of future performance or the ability
to identify and consummate investments. Many of these risks and
uncertainties relate to factors that are beyond each of Amryt's
ability to control or estimate precisely, such as future market
conditions, the course of the COVID-19 pandemic, currency
fluctuations, the behaviour of other market participants, the
outcome of clinical trials, the actions of regulators and other
factors such as Amryt's ability to obtain financing, changes in the
political, social and regulatory framework in which Amryt operates
or in economic, technological or consumer trends or conditions.
Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or
implied, is made regarding future performance. No person is under
any obligation to update or keep current the information contained
in this announcement or to provide the recipient of it with access
to any additional relevant information that may arise in connection
with it. Such forward-looking statements reflect the Company's
current beliefs and assumptions and are based on information
currently available to management.
Contacts
Joe Wiley, CEO, +353 (1) 518 0200, joe.wiley@amrytpharma.com
Rory Nealon, CFO/COO, +353 (1) 518 0200,
rory.nealon@amrytpharma.com
Edward Mansfield, Shore Capital, NOMAD, +44 (0) 207 468 7906,
edward.mansfield@shorecap.co.uk
Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564,
tim@lifesciadvisors.com
Amber Fennell, Consilium Strategic Communications, +44 (0) 203
709 5700, fennell@consilium-comms.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUVSWRAKUARAR
(END) Dow Jones Newswires
January 06, 2021 02:00 ET (07:00 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024